Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase I / Phase II
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Trial testing two new cell therapies (KITE-363 and KITE-753) for B-cell lymphoma that hasn't responded to standard treatment.
24 Apr 2026 NCT04989803
active not recruiting Phase II
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
A trial testing whether tebapivat reduces blood transfusion needs in patients with low-risk bone marrow disorders.
24 Apr 2026 NCT05490446
active not recruiting Phase II / Phase III
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Diacerein ointment tested for safety and effectiveness in treating generalized epidermolysis bullosa simplex blistering disorder.
24 Apr 2026 NCT06073132
active not recruiting Phase I / Phase II Oncology
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Trial testing durvalumab combinations versus standard chemotherapy in patients with advanced triple negative breast cancer.
24 Apr 2026 NCT03742102
● Recruiting Phase II Dermatology
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Trial testing different doses of galvokimig versus placebo in adults with moderate-to-severe eczema to find the most effective safe dose.
24 Apr 2026 NCT07277660
● Recruiting Phase II Respiratory / COPD / Asthma
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
What is being tested: Imlifidase, an IgG-degrading enzyme, is being evaluated for its efficacy and safety in enabling successful kidney transplantation in highly sensitized…
24 Apr 2026 NCT05753930
● Recruiting Phase II Oncology
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
What is being tested: Pumitamig (BNT327), a novel investigational therapy, combined with chemotherapy as first-line or second-line treatment in advanced/metastatic NSCLC, with evaluation of…
24 Apr 2026 NCT06841055
● Recruiting Phase II / Phase III
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
A trial testing whether an oral cholesterol-lowering drug is safe and effective in children and teenagers with familial high cholesterol.
23 Apr 2026 NCT07058077
active not recruiting Phase II / Phase III
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Mitapivat tested in sickle cell patients to increase haemoglobin levels and reduce painful crisis episodes compared to placebo.
23 Apr 2026 NCT05031780
active not recruiting Phase II
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Trial testing tebapivat against placebo in sickle cell disease patients to find the best dose for improving hemoglobin levels.
23 Apr 2026 NCT06924970
active not recruiting Phase II Rheumatology
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
A new drug (LY3871801) is being tested for safety and effectiveness in adults with moderate-to-severe rheumatoid arthritis.
23 Apr 2026 NCT05848258
● Recruiting Phase II Respiratory / COPD / Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
What is being tested: KT-621, an oral investigational agent, is being evaluated in a Phase 2b trial to assess its safety and efficacy in…
23 Apr 2026 NCT07323654
● Recruiting Phase II Oncology
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
What is being tested: The efficacy and safety of combined trastuzumab and pertuzumab (two HER2-targeted monoclonal antibodies) across multiple cancer types with HER2 amplification…
23 Apr 2026 NCT05786716
● Recruiting Phase II Infectious Disease
A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection
What is being tested: Extended high-dose antibiotic treatment combined with methenamine hippurate versus standard care (low-dose prophylactic antibiotics or methenamine hippurate alone) for managing…
23 Apr 2026 NCT07202949
● Recruiting Phase II Oncology
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
What is being tested: Novel agents or novel combination therapies administered perioperatively (before and after surgery) in patients with locally advanced resectable gastric, gastroesophageal…
23 Apr 2026 NCT07069712
● Recruiting Phase I / Phase II
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
ADX-038, a new drug for rare blood disorder PNH, was tested for safety and effectiveness in healthy people and patients.
22 Apr 2026 NCT05876312
● Recruiting Phase II
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves’ Disease
New drug IMVT-1402 tested against placebo in adults with Graves' disease uncontrolled by standard thyroid medications.
22 Apr 2026 NCT06727604
● Recruiting Phase II
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Momelotinib tested for safety and effectiveness in reducing blood transfusion needs in early-stage myelodysplastic syndrome patients.
22 Apr 2026 NCT06847867
● Recruiting Phase II
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
ALXN1920 (a complement C3 inhibitor) is being tested against placebo in adults with primary membranous nephropathy, with efficacy measured by reduction in 24-hour urine…
22 Apr 2026 NCT07157787
● Recruiting Phase II
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Drug being tested: ADX-038, a novel therapeutic agent targeting complement-mediated pathways, is being evaluated for safety, efficacy, and how the body processes and responds…
22 Apr 2026 NCT06989359
● Recruiting Phase II
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
AGA2115 tested against placebo in adults with osteogenesis imperfecta caused by COL1A1 or COL1A2 gene mutations.
21 Apr 2026 NCT07062588
active not recruiting Phase I / Phase II Oncology
Durvalumab and Tremelimumab for Pediatric Malignancies
Study testing safe doses of two immunotherapy drugs in children with advanced cancers, then checking if they work.
21 Apr 2026 NCT03837899
● Recruiting Phase II Rheumatology
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Tulisokibart (MK-7240) is being tested to see if it can improve symptoms of radiographic axial spondyloarthritis better than placebo.
20 Apr 2026 NCT07133633
active not recruiting Phase II
Extended Access of Momelotinib in Adults With Myelofibrosis
Momelotinib Extended Access Trial Summary This study provides ongoing access to momelotinib for myelofibrosis patients and monitors long-term safety and survival.
20 Apr 2026 NCT03441113
active not recruiting Phase I / Phase II
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
BION-1301 was tested for safety and tolerability in healthy people and IgA kidney disease patients.
20 Apr 2026 NCT03945318
● Recruiting Phase II Oncology
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
What is being tested: Novel therapeutic interventions and their combinations for colorectal cancer treatment, with primary focus on evaluating safety profiles and clinical efficacy…
20 Apr 2026 NCT06792695
● Recruiting Phase II Rheumatology
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
What is being tested: Iptacopan (LNP023), a complement factor B inhibitor, is being evaluated as an add-on therapy to standard care in patients with…
20 Apr 2026 NCT05268289
● Recruiting Phase II Women's Health
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
A study testing whether vipoglanstat reduces pelvic pain in women with endometriosis, beyond pain linked to periods.
17 Apr 2026 NCT07260669
active not recruiting Phase II
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
Trial testing whether BI 764524 injection helps moderate-to-severe diabetic retinopathy, comparing different dosing schedules against sham control.
17 Apr 2026 NCT06321302
● Recruiting Phase I / Phase II
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Phase 1/2 trial testing oral pirtobrutinib for immune thrombocytopenia, evaluating safety, tolerability, and effectiveness at different doses.
17 Apr 2026 NCT06721013
● Recruiting Phase II Oncology
NEOadjuvant PembRolizumab In Stratified Medicine – ColoRectal Cancer
What is being tested: Neoadjuvant pembrolizumab (an anti-PD-1 immunotherapy) combined with standard chemotherapy and/or radiotherapy in stratified cohorts of early-stage colorectal cancer patients, assessed…
17 Apr 2026 NCT05197322
● Recruiting Phase II Neurology
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer’s Disease Dementia
What is being tested: EXV-802 and EXV-801 are novel investigational agents being evaluated for their safety and efficacy in treating agitation symptoms in patients…
17 Apr 2026 NCT07284472
● Recruiting Phase II Oncology
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
What is being tested: Novel immunomodulators administered as monotherapy and in combination with anticancer agents to evaluate their efficacy, safety, and tolerability in advanced…
17 Apr 2026 NCT05775159
● Recruiting Phase II Diabetes / Metabolic
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
What is being tested: LY3457263, a novel investigational agent, is being evaluated as an add-on therapy to semaglutide or tirzepatide in patients whose blood…
17 Apr 2026 NCT06897475
active not recruiting Phase II
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Spinal fluid injections of SHP611 tested to slow movement decline in children with metachromatic leukodystrophy.
15 Apr 2026 NCT03771898
● Recruiting Phase II Oncology
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Inobrodib combined with pomalidomide and dexamethasone shows promise in treating multiple myeloma that resists standard therapies.
15 Apr 2026 NCT07096778
● Recruiting Phase II Oncology
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Treatment being tested: RO7198457 (an investigational targeted therapy) is being compared against watchful waiting in patients with detectable circulating tumor DNA (ctDNA) following surgical…
15 Apr 2026 NCT04486378
● Recruiting Phase II Diabetes / Metabolic
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Intervention tested: Vicadrostat (a novel selective aldosterone synthase inhibitor) combined with empagliflozin (an SGLT2 inhibitor) in adults with progressive chronic kidney disease, building on…
15 Apr 2026 NCT06926660
● Recruiting Phase II Oncology
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
What is being tested: Autologous LN-145, a tumor-infiltrating lymphocyte (TIL) therapy administered to patients with metastatic non-small-cell lung cancer (NSCLC) in a phase 2…
15 Apr 2026 NCT04614103
● Recruiting Phase II Oncology
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
What is being tested: BNT327 (an investigational agent) combined with chemotherapy and other experimental drugs in first-line treatment of non-small cell lung cancer (NSCLC),…
15 Apr 2026 NCT06712316
● Recruiting Phase II Diabetes / Metabolic
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
What is being tested: KL1333, a novel therapeutic agent, is being evaluated for its efficacy in reducing disease manifestations of primary mitochondrial disease (PMD),…
15 Apr 2026 NCT05650229
● Recruiting Phase II Cardiology / Cardiovascular
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
What is being tested: Pelacarsen (TQJ230), a subcutaneous antisense oligonucleotide that lowers lipoprotein(a), is being evaluated against placebo to determine whether reducing Lp(a) levels…
15 Apr 2026 NCT05646381
● Recruiting Phase I / Phase II
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Early-stage trial testing a new oral drug (nuvisertib) for safety and effectiveness in myelofibrosis patients.
14 Apr 2026 NCT04176198
active not recruiting Phase II Oncology
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
FAIM Trial Summary Adding ipatasertib to fulvestrant and palbociclib may improve survival in advanced hormone-receptor positive breast cancer patients without early treatment response.
14 Apr 2026 NCT04920708
active not recruiting Phase II Oncology
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Adults who previously tolerated brigimadlin continue taking tablets every three weeks to assess long-term safety and tumour response.
14 Apr 2026 NCT06619509
● Recruiting Phase II
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
Long-term safety and efficacy study of lunsekimig (a new treatment) in adults with poorly controlled chronic rhinosinusitis with nasal polyps over 52 weeks.
14 Apr 2026 NCT06914908
● Recruiting Phase II Oncology
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
What is being tested: Long-term safety monitoring of enzalutamide in prostate cancer patients who are continuing to benefit from treatment in previous Astellas or…
14 Apr 2026 NCT02960022
● Recruiting Phase II Oncology
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
What is being tested: Amivantamab (a bispecific antibody targeting EGFR and MET) administered subcutaneously with recombinant human hyaluronidase in combination regimens, primarily for advanced/metastatic…
14 Apr 2026 NCT05498428
● Recruiting Phase II Oncology
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Treatment being tested: Amivantamab (a bispecific antibody) combined with either lazertinib (a third-generation EGFR tyrosine kinase inhibitor) or platinum-based chemotherapy in patients with EGFR-mutated…
14 Apr 2026 NCT06667076
● Recruiting Phase II Oncology
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
What is being tested: Inavolisib (a PI3K inhibitor) combined with fulvestrant (an oestrogen receptor degrader) in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced…
14 Apr 2026 NCT07368998